Skip to main content

Advertisement

Figure 3 | BMC Cancer

Figure 3

From: Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections

Figure 3

Distribution of positive and negative mARs in BPH and prostate carcinoma. Ninety % of benign prostate hyperplasia cases (n = 103) were negative for mAR receptor expression. On the other hand, prostate carcinoma cases (n = 106) showed mAR expression in a significant percentage (38% of these cases were positive) (χ2 = 16.7, p < 0.0001).

Back to article page